Rationalizing cyclooxygenase inhibition for optimization of efficacy and safety profiles. Proceedings of a workshop. Fort Worth, Texas, USA. February 1999.
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002074:Butanones / Q000009:adverse effects; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004064:Digestive System / Q000187:drug effects*; D006801:Humans; D007527:Isoenzymes / Q000494:pharmacology*; D000077239:Meloxicam; D008565:Membrane Proteins; D000077430:Nabumetone; D011451:Prostaglandin-Endoperoxide Synthases / Q000494:pharmacology*; D013843:Thiazines / Q000009:adverse effects; D013844:Thiazoles / Q000009:adverse effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002074:Butanones; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D013843:Thiazines; D013844:Thiazoles; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000077430:Nabumetone; D000077239:Meloxicam